The SYNCAN project: Goals, set-up, first results and settings of the human intervention study

British Journal of Nutrition

Volumn 93, Issue SUPP, 2005, Pages

  Van Loo, Jan ^a   Clune, Yvonne ^b   Bennett, Mary ^b   Collins, John Kevin ^b  

^a ORAFTI   (Belgium)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bifidobacterium; Colon cancer; Inulin; Lactobacillus; Man; Oligofructose

Indexed keywords

FRUCTAN; INULIN; PREBIOTIC AGENT; PROBIOTIC AGENT; RAFTILOSE; OLIGOFRUCTOSE; OLIGOSACCHARIDE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIFIDOBACTERIUM ANIMALIS; CANCER GROWTH; CANCER RISK; CANCER SURGERY; CELL FREE SYSTEM; COLON CANCER; CONTROLLED STUDY; DRUG DECOMPOSITION; GOAL ATTAINMENT; HUMAN; IN VITRO STUDY; INTERVENTION STUDY; LACTOBACILLUS RHAMNOSUS; MAJOR CLINICAL STUDY; NONHUMAN; RAT; ANIMAL; BIFIDOBACTERIUM; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; DIETARY FIBER; LACTOBACILLUS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; RISK;

ANIMALIA; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; CICHORIUM INTYBUS; LACTOBACILLUS; LACTOBACILLUS RHAMNOSUS;

ANIMALS; BIFIDOBACTERIUM; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DIETARY FIBER; HUMANS; INULIN; LACTOBACILLUS; MODELS, ANIMAL; OLIGOSACCHARIDES; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS; RATS; RESEARCH DESIGN; RISK;

EID: 23044454651     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1079/BJN20041353     Document Type: Article

References (26)

1. Bolognani F, Rumney CJ, Pool-Zobel BL & Rowland IR (2001) Effect of lactobacilli, bifidobacteria and inulin on the formation of aberrant crypt foci in rats. Eur J Nutr 40, 293-300.
2. Dunne C, Murphy L, Flynn S, et al. (1999) Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek 76, 279-292.
3. Dunne C, O'Mahony L, Murphy L, et al. (2001) In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 73, Suppl., 386S-392S.
4. Femia AP, Luceri C, Dolara P, Giannini A, Biggeri A, Salvadori M, Clune Y, Collins KJ, Paglierani M & Caderni G (2002) Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis 23, 1953-1960.
5. Gallaher DD, Stallings WH, Blessing LL, Busta FF & Brady LJ (1996) Probiotics, cecal microflora, and aberrant crypts in the rat colon. J Nutr 126, 1362-1371.
6. Hartemink R, Kok BJ, Weenk GH & Rombouts FM (1996) Raffinose-Bifidobacterium (RB) agar, a new selective medium for bifidobacteria. J Microbiol Methods 27, 33-43.
7. Klinder A, Förster A, Caderni G, Femia AP & Pool-Zobel BL (2004) Fecal water genotoxicity is predictive of tumor preventive activities by inulin-like oligofructoses, probiotics (Lactobacillus rhamnosus and Bifidobacterium lactis) and their synbiotic combination. Nutr Cancer 49, 144-155.
8. Klinder A, Gietl E, Hughes R, Jonkers N, Pistoli S, Gibson G, Rowland I, Van Loo J & Pool-Zobel B (2003) Gut fermentation products of inulin-derived prebiotics inhibit markers of tumor progression in human colon tumor cells. J Cancer Prev 1, 19-32.
9. Kruse HP, Kleessen B & Blaut M (1999) Effects of inulin on faecal bifidobacteria in human subjects. Br J Nutr 82, 375-382.
10. Kulkarni N & Reddy BS (1994) Inhibitory effect of Bifidobacterium longum cultures on the azoxymethane-induced aberrant crypt foci formation and fecal bacterial beta-glucuronidase. Proc Soc Exp Biol Med 207, 278-283.
11. McBain AJ & Macfarlane GT (1997) Investigations of bifidobacterial ecology and oligosaccharide metabolism in a three-stage compound continuous culture system. Scand J Gastroenterol Suppl 22, 232-240.
12. O'Mahony L, Feeney M, O'Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O'Sullivan G, Shanahan F & Collins JK (2001) Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 15, 219-225.
13. Pierre F, Perrin P, Champ M, Bornet F, Meflah K & Menanteau J (1997) Short-chain fructo-oligosaccharides reduce the occurrence of colon tumors and develop gut-associated lymphoid tissue in Min mice. Cancer Res 57, 225-228.
14. Rao VA (2001) The prebiotic properties of oligofructose at low intake levels. Nutr Res 21, 843-848.
15. Reddy BS, Hamid R & Rao CV (1997) Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition. Carcinogenesis 18, 1371-1374.
16. Roller M, Rechkemmer G & Watzl B (2004á) Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats. J Nutr 134, 153-156.
17. Roller M, Femia AP, Caderni G, Rechkemmer G & Watzl B (2004b) Intestinal immunity of rats with colon cancer is modulated by oligofructose-enriched inulin combined with Lactobacillus rhamnosus and Bifidobacterium lactis. Br J Nutr 92, 931-938.
18. Rowland IR, Rumney CJ, Coutts JT & Lievense LC (1998) Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 19, 281-285.
19. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, Isolauri E, Moreau MC, Roberfroid M & Rowland I (1998) Functional food science and gastrointestinal physiology and fucntion. Br J Nutr 80, Suppl. 1, S147-S171.
20. Taper HS, Lemort C & Roberfroid MB (1998) Inhibition effect of dietary inulin and oligofructose on the growth of transplantable mouse tumor. Anticancer Res 18, 4123-4126.
21. Taper HS & Roberfroid M (1999) Influence of inulin and oligofructose on breast cancer and tumor growth. J Nutr 129, Suppl., 1488S-1491S.
22. Taper HS & Roberfroid MB (2000) Inhibitory effect of dietary inulin or oligofructose on the development of cancer metastases. Anticancer Res 20, 4291-4294.
23. Van Loo J (2004) The specificity of the interaction with intestinal fermentation by prebiotics determines their physiological efficacy. Nutr Res Rev 17, 89-98.
24. Van Loo J & Jonkers N (2001) Evaluation in human volunteers of the potential anticarcinogenic activities of novel nutritional concepts: prebiotics, probiotics and synbiotics (the SYNCAN project QLK1-1999-00346). Nutr Metab Cardiovasc Dis 11, 87-93.
25. Verghese M, Rao DR, Chawan CB, Williams LL & Shackelford LA (2002) Dietary inulin suppresses azoxymethane-induced aberrant crypt foci and colon tumors at the promotion stage in young Fisher 344 rats. J Nutr 132, 2809-2813.
26. Verghese M, Walker LT, Shackelford LA, Chawan CB & Van Loo J (2003) Inhibitory effects of non-digestible carbohydrates of different chain lengths on AOM induced aberrant crypt foci in Fisher 344 rats. In Proceedings of the Second Annual AACR International Conference. Frontiers in Cancer Prevention Research, Phoenix, AZR, 26-30 October 2003. Poster B186 Abstr.